Genmab — Maj 2025
-
IF Rina-S will really prove to be best in class as was being suggested on the call, it could be a complete game changer for Genmab. Definetely not priced in. I could make as much revenue as we currently make on Darzalex since it is 100%. Good ASCO data could potentially get investors to update guidance already
-
sure. but if you don't have the aspirations you'll never get there. It also works the other way around right -if you have a drug that gives you the confidence it will be a big seller, it will also give you the confidence to ramp up the sales organisation.
-
Godmorgen

-
Trump vil presse medicinpriserne markant ned i USA https://www.dr.dk/nyheder/udland/trump-vil-saenke-priserne-paa-medicin-i-usa-markant
-
"Nyhedsbureauet AP skriver, at Trumps forslag sandsynligvis kun vil sænke priserne på de lægemidler, der er dækket af den offentlige sundhedsforsikring Medicare.
Medicare udgør en hjørnesten i det amerikanske sundhedssystem og sikrer sundhedsdækning for omkring 70 millioner ældre borgere".
-
Er Donald Trump medicinmanden med de lavere priser? https://proinvestor.com/boards/126321
-
Dose Selection for DuoBody
-CD40x4-1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.3677 -
Vi får en ordentlig en på hatten lige nu. Lad os se hvad der sker i løbet af dagen. Sidste gang han forsøgte noget lignende blev han jo stoppet af domstolene.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind